Ryan, David P.

Pancreatic adenocarcinoma

Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 2,348

Frequent Mutation of Isocitrate Dehydrogenase(IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 728

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Cited by 518

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 507

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics

Pancreatic and Hepatic Oncology ResearchSingle-cell and spatial transcriptomics

Cited by 426

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 297

The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer

Nipp, R. D., El‐Jawahri, A., Moran, S. M., D'Arpino, S. M., Johnson, P. C., Lage, D. E., Wong, R. L., Pirl, W. F., Traeger, L., Lennes, I. T., et al. (2017) · Cancer

Palliative Care and End-of-Life IssuesPalliative and Oncologic Care

Cited by 230

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 210

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs

Pancreatic and Hepatic Oncology ResearchChemokine receptors and signaling

Cited by 199

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 197

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

Roh, M. S., Yothers, G. A., O'Connell, M. J., Beart, R. W., Pitot, H. C., Shields, A. F., Parda, D. S., Sharif, S., Allegra, C. J., Petrelli, N. J., et al. (2011) · Journal of Clinical Oncology

Colorectal Cancer Surgical TreatmentsColorectal and Anal Carcinomas

Cited by 194

Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism

Patra, K. C., Kato, Y., Mizukami, Y., Widholz, S., Boukhali, M., Revenco, I., Grossman, E. A., Ji, F., Sadreyev, R. I., Liss, A. S., et al. (2018) · Nature Cell Biology

Pancreatic and Hepatic Oncology ResearchCancer, Lipids, and Metabolism

Cited by 192

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research

Cholangiocarcinoma and Gallbladder Cancer StudiesCancer Genomics and Diagnostics

Cited by 138

Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma

Porter, R. L., Magnus, N. K. C., Thapar, V., Morris, R., Szabolcs, A., Neyaz, A., Kulkarni, A. S., Tai, E., Chougule, A., Hillis, A., et al. (2019) · Proceedings of the National Academy of Sciences

Pancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cited by 129

Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma

Liu, H., Naxerova, K., Pinter, M., Incio, J., Lee, H., Shigeta, K., Ho, W. W., Crain, J. A., Jacobson, A., Michelakos, T., et al. (2017) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchPeptidase Inhibition and Analysis

Cited by 96

Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer.

Rajurkar, M., Parikh, A. R., Solovyov, A., You, E., Kulkarni, A. S., Chu, C., Xu, K. H., Jaicks, C., Taylor, M. S., Wu, C., et al. (2022) · Cancer Discovery

Chromosomal and Genetic VariationsCancer-related molecular mechanisms research

Cited by 61

Processes of code status transitions in hospitalized patients with advanced cancer

El‐Jawahri, A., Lau‐Min, K., Nipp, R. D., Greer, J. A., Traeger, L. N., Moran, S. M., D'Arpino, S. M., Hochberg, E. P., Jackson, V. A., Cashavelly, B. J., et al. (2017) · Cancer

Palliative Care and End-of-Life IssuesPalliative and Oncologic Care

Cited by 33

Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center

Zubiri, L., Rosovsky, R. P., Mooradian, M. J., Piper-Vallillo, A. J., Gainor, J. F., Sullivan, R. J., Marte, D., Boland, G. M., Gao, X., Hochberg, E. P., et al. (2021) · The Oncologist

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 19

The impact of skin cancer prevention efforts in New South Wales, Australia: Generational trends in melanoma incidence and mortality

Blazek, K., Furestad, E., Ryan, D., Damian, D., Fernandez-Penas, P., & Tong, S. (2022) · Cancer Epidemiology

Cutaneous Melanoma Detection and ManagementGlobal Cancer Incidence and Screening

Cited by 18